<- Go Home
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Market Cap
$795.4M
Volume
1.8M
Cash and Equivalents
$41.3M
EBITDA
-$178.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$50.7M
Profit Margin
60.13%
52 Week High
$18.90
52 Week Low
$6.66
Dividend
N/A
Price / Book Value
6.96
Price / Earnings
-4.60
Price / Tangible Book Value
7.97
Enterprise Value
$718.9M
Enterprise Value / EBITDA
-4.04
Operating Income
-$179.4M
Return on Equity
92.33%
Return on Assets
-33.04
Cash and Short Term Investments
$245.0M
Debt
$168.5M
Equity
$114.3M
Revenue
$84.3M
Unlevered FCF
-$93.0M
Sector
Biotechnology
Category
N/A